Last updated on May 2019

An Investigational Immuno-therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Patients With Solid Cancers That Are Advanced or Have Spread


Brief description of study

The purpose of the study is to determine the safety and tumor-shrinking ability of experimental medication BMS-986178, when given by itself or in combination with Nivolumab and/or Ipilimumab, in patients with solid cancers that are advanced or have spread.

Clinical Study Identifier: NCT02737475

Find a site near you

Start Over

H. Univ. Vall dHebron

Barcelona, Spain
3.77miles
  Connect »